Lymphoma News ECHELON-2 Trial Demonstrates “Practice-Changing” Results for Peripheral T-Cell Lymphomas
Lymphoma News FDA Approves Ibrutinib (IMBRUVICA) in Combination with Obinutuzumab (GAZYVA) for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Lymphoma News U.S. Food and Drug Administration Approves Brentuximab Vedotin (ADCETRIS) for Frontline Treatment of Peripheral T-Cell Lymphoma (PTCL)
Lymphoma News U.S. Food and Drug Administration Approves Duvelisib (COPIKTRA) for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Follicular Lymphoma
Lymphoma News U.S. Food and Drug Administration Approves Ibrutinib (IMBRUVICA) Plus Rituximab (RITUXAN) for Waldenström Macroglobulinemia (WM)
Lymphoma News U.S. Food and Drug Administration Approves Mogamulizumab-kpkc (Poteligeo) for Two Most Common Types of Cutaneous T-Cell Lymphoma
Lymphoma News U.S. Food and Drug Administration Approves Pembrolizumab (Keytruda) for Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma (PMBCL)
Lymphoma News U.S. Food and Drug Administration Approves Venetoclax (VENCLEXTA) For Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia – With or Without 17p Deletion
Lymphoma News U.S. Food and Drug Administration Approves Tisagenlecleucel For Relapsed/ Refractory Large B-cell Lymphoma